Physician profile
Tan Tran
NPI 1285621052
$11,738.90
in general payments reported to CMS, 2019-2025
42 companies · $1,854 in 2025
The $1,854 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,873 · 2020: $2,039 · 2021: $1,693 · 2022: $1,651 · 2023: $1,257 · 2024: $1,372 · 2025: $1,854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,483.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,553.00 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,458.51 | 2019-2025 | Jardiance, Synjardy |
| Abbvie INC. | $1,282.06 | 2021-2025 | Vraylar, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $721.77 | 2022-2025 | |
| Glaxosmithkline, LLC. | $698.19 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $658.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $630.21 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amarin Pharma, INC. | $566.35 | 2019-2022 | |
| Astellas Pharma US INC | $559.31 | 2019-2024 | Veozah, Myrbetriq |
| Gilead Sciences, INC. | $430.54 | 2019-2025 | |
| Indivior INC. | $418.06 | 2019-2025 | Sublocade |
| Amgen INC. | $400.07 | 2019-2025 | Repatha, Otezla, Otezla |
| Antares Pharma, INC. | $361.38 | 2019-2023 | Xyosted, Tlando, Nocdurna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $275.45 | 2019-2023 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $274.40 | 2019-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tan Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.